Avoiding Healthcare Cost With Pricing Transparency Hype

No less than two reports have been published final week which fall loosely underneath the banner of healthcare pricing transparency.

The 1st was Medscape’s Physician Compensation Report for 2014 (right here). The annual Medscape report is based mostly on a survey of in excess of 24,000 physicians in 25 specialties around a broad range of compensation troubles – including satisfaction.

Medscape’s findings (with data from 2013) is marginally far more insightful than the Medicare Information dump from 2 weeks in the past (here). 1 of glaring inadequacies of the Medicare data (for 2012) is the simple reality that income isn’t compensation. Seeing an annual summary of what Medicare paid to individual suppliers has practically no patient use.

In accordance to the Medscape report (slides right here) there weren’t many big swings in compensation (there seldom are), but there’s usually a few noteworthy shifts. No significantly less than 19 of the 25 various practice regions noticed an improve in compensation from the prior year, 1 was neutral and five saw a decrease. Of the decreases, only 1 (nephrology) saw an 8% decline in compensation. Three of the remaining four saw a 2% decline.

All round satisfaction was close to or over 50% for most of the specialties across 4 categories (Total, Income, Career and Specialty). The two noteworthy exceptions have been Loved ones &amp Internal Medication with 32% and 27% (respectively for decision of specialty) even even though they appeared to be comparatively content (50% &amp 46%) with their income. Other findings as quoted from the slide notes:

• Those who carry out procedures have the highest incomes compared with individuals who manage chronic illnesses. Earnings are for total-time function only. They include salary, bonus, and profit-sharing contributions. They do not consist of non-patient-connected earnings.


• In this year’s Medscape report, the perception of being relatively compensated does not correlate to real compensation for several doctors. Orthopedists had been the most hugely paid physicians, but they fell under the middle of this record, with only 45% believing that they are fairly compensated. And despite the fact that plastic surgeons were seventh between the leading earners, at 37% they have been the least most likely of all physicians to think that they are fairly paid.


• When evaluating newer payment versions with survey results from 2011, there has been a dramatic rise in doctors choosing ACOs, with 24% of all doctors now employed in these organizations vs only 3% in 2011. Moreover, ten% are planning on joining this yr. In spite of considerable publicity, income-only and concierge practices are nonetheless not significant payment designs.


• 5% of employed and 15% of self-employed doctors explained that they will not get new Medicare or Medicaid patients.


• Although Medicare is known to have lowered fees, private insurers are also paying less, especially to modest practices without having any strong influence. Robert Morrow, MD, a family members physician in the Bronx and a Medscape advisor, mentioned he now receives $ 82 from Medicare for an office visit but only about $ 45 from commercial insurers.


• About 72% of respondents to this survey routinely or sometimes go over the expense of treatment method with individuals. This has gone up from 68% in 2012.


• 35% of employed doctors devote at least ten hrs a week on paperwork compared with 26% of the self-employed.

The second report – Price Transparency in Overall health Care (PDF right here) – was from the Healthcare Financial Management Association (HFMA). For people unfamiliar with HFMA, their site (right here) describes the organization this way:

HFMA is the nation’s top membership organization for healthcare monetary management executives and leaders. More than forty,000 members-ranging from CFOs to controllers to accountants-consider HFMA a respected believed leader on best trends and troubles dealing with the healthcare industry. 

In fairness, they exclusively indicate that the “primary audience for this report is sector stakeholders in provider, payer, and purchaser settings that this report calls upon to take distinct actions to improve the transparency of healthcare prices” (ie: not customers or sufferers).

The conclusion from HFMA’s 20-page report is just this:

The lack of price transparency in well being care threatens to erode public believe in in our healthcare system, but this erosion can be stopped. Sufferers are assuming greater financial accountability for their healthcare needs and in turn need the data that will permit them to make informed healthcare selections. Price is not the only details needed to make these selections as this report has mentioned, cost must be presented in the context of other relevant data on the quality of care. But it is an important element. The time for price transparency in well being care is now.

I have grave doubts about stopping the erosion of public trust. Two of the seven headings are “Guiding Ideas for Value Transparency” and “Recommendations for Price tag Transparency Frameworks.” In impact, it’s generally another market “call to action.”

Sadly, the worth of any of this “transparency” is truly marginal – either in terms of our own actions – or in terms of the influence on our Nationwide Healthcare Expenditure (NHE). The Centers for Medicare and Medicaid (CMS) forecasts our NHE to be $ 3.1 trillion this 12 months. In reality, our NHE as forecasted by CMS (Table one web page five right here) seems to be like this through 2022 (the two with and without Obamacare).

All of which tends to make this type of transparency comparable to rubbernecking a freeway accident. There’s a short minute of anxiousness and tension and then everyone speeds on their way. Assuming data accuracy, releasing any healthcare pricing is a hollow objective because there is virtually nothing at all any person can do with it. We merely have no way to influence it – either individually or collectively – and absent quality (or clinical outcomes), there is no way to equate any worth. We may possibly as properly use random amount generators.

The 1 point it constantly does, nonetheless, is to highlight how significantly our healthcare program is optimized all around income and earnings. Possibly someday this will translate into a debate about real healthcare reform – the one we continually keep away from (cough – SGR / “doc fix” – cough). That debate is not called transparent anything. Its known as healthcare cost.

Avoiding Healthcare Cost With Pricing Transparency Hype

Can resveratrol the "wonder chemical" in red wine live up to the hype? | Corrinne Burns

In an increasingly chemophobic planet, one particular chemical – resveratrol – is performing rather effectively for itself. This polyphenolic stilbenoid is a all-natural product identified in peanuts, cocoa powder and the roots of Japanese knotweed, but it only came to public prominence as the wellness-promoting element of red wine, in which it is current at amounts of up to 14 milligrams per litre, depending on the grape variety.

As molecules go, it is surely a multitasker, with purported activity towards cardiac disease, obesity, cancer, vascular dementia and ageing. That is a good deal of pressure to place on a single molecule. Can resveratrol dwell up to our expectations?

Many of these claims centre on its ability to minimize oxidation in cells: its fabled antioxidant exercise. All molecules, including biological ones, carry all around their personal cloud of electrons. These are most stable when they exist in pairs. At times, however, electron pairs split. Then you are left with an unpaired electron – and unpaired electrons like nothing more than to mess with other biological molecules.

Left unchecked, molecules carrying unpaired electrons can trigger cascades of injury to other molecules in our cells. Resveratrol is considered to interrupt those destructive cascades by transferring electrons and hydrogen atoms among itself and troublesome, lone-electron-carrying molecules.

Resveratrol can do significantly a lot more than that, however. It encourages the manufacturing of endothelial nitric oxide, which dilates blood vessels. Researchers have demonstrated that this potential to open up blood vessels indicates resveratrol can safeguard towards hypertension – at least in rats and mice. It is also an anti-inflammatory, disrupting the action of an enzyme referred to as cyclooxygenase-2 (COX-2), which is critical to the manufacturing of inflammatory prostaglandins.

There are reams of papers about the “in vitro” anti-tumour activity of resveratrol (killing tumour cells in a dish in lab experiments), and numerous purported mechanisms of action. Several of these involve resveratrol altering the exercise of various genes and proteins involved in cellular proliferation and death.

And resveratrol’s supposed anti-ageing action does have some basis in animal experiments, with studies showing that dietary supplements can slow some of the metabolic facets of the ageing process in a way equivalent to calorie-restriction diets.

It all sounds marvellous. What a molecule! But of course the reality is not so clearcut. Resveratrol’s antioxidant properties may possibly be a double-edged sword, for instance. In the popular press “antioxidant action” is talked about as however it is an unambiguously Excellent Thing. But we need some oxygen-containing molecules with unpaired electrons – acknowledged as “reactive oxygen species” – because they are element of our typical immune response. This could clarify why, earlier this year, Swedish researchers reported that antioxidants can truly make tumours increase much more quickly in rodents.

And, annoyingly for these of us who drag ourselves round the block prior to operate each and every morning, one more review suggested that resveratrol could wipe out the helpful results of workout.

It is not unusual to find this kind of conflicting information in the messy globe of analysis. What happens amongst molecule and cell in the neat, orderly world of a cell culture in a laboratory is not always reflected in our three-dimensional, multi-tissued, metabolically dynamic bodies.

But buried underneath all the hype about resveratrol, is there still clinical likely? “I can picture a role [for resveratrol] in the prevention of colon cancer,” says Dr Randolph Arroo, head of investigation at Leicester College of Pharmacy and a expert in phytochemistry. “The absorption characteristics for resveratrol are generally really poor, but in the intestines realistic concentrations of resveratrol, or its metabolites, can be maintained.”

He is far more sceptical about resveratrol’s capability to reduce the danger of other illnesses, even though, citing the molecule’s bad bioavailability – it may operate effectively in vitro, but is absorbed poorly and doesn’t hang close to in the bloodstream prolonged enough to get to the locations exactly where it may do us very good. “The bioavailability of resveratrol is so bad that the concentrations that are necessary to get the effects observed in in vitro cell cultures are never accomplished in the body (in vivo) for a prolonged time period.”

To address this problem, research is ongoing into semi-synthetic derivatives of resveratrol that may be a lot more efficient than the all-natural merchandise.

Right now, the only way to get a dose of pure resveratrol is by in excess of-the-counter supplements – and the marketing of these tends to emphasis on the molecule’s supposed cosmetic benefits. Food supplement producer Fountain claims that 1 of its most widely publicised products, the “Beauty Molecule”, is the 1st water-soluble resveratrol formulation, enabling for highest absorption and therefore advertising “health, youth and longevity”.

I contacted Fountain to ask about their resveratrol investigation – I was interested in how this novel formulation was metabolised and distributed inside the physique. Unfortunately, at the time of creating, the business had been unable to offer me with its data.

So to come back to our unique question: is resveratrol genuinely worthy of all the attention? Dr Arroo believes that if the molecule was identified only in, say, a minor-known Chinese herb rather than red wine, it would have attracted far significantly less curiosity. But he is nonetheless glad the molecule is obtaining noticed: “Resveratrol is a ‘chemical’ but it comes from berries and grapes. It can make individuals aware that fruits and greens are manufactured of chemical substances.”

So could resveratrol be powerful against chemophobia, too?

Can resveratrol the "wonder chemical" in red wine live up to the hype? | Corrinne Burns

Tobacco companies hype smuggling fears to steer clear of plain packaging, finds review

The standardised packaging which is now necessary for cigarettes in Australia. Official figures from Australian customs say smuggling has not elevated. Photograph: Tim Wimborne/Reuters

Tobacco companies have been accused of encouraging scare stories claiming that the introduction of plain cigarette packs would promote smuggling.

A peer-reviewed examine has located that, far from the sector currently being a victim of smuggling, there are credible allegations that it has been complicit in facilitating unlawful trade in its items.

A report by Sir Cyril Chantler, reviewing the public wellness rewards of plain packaging, is due to be delivered to the government this week. It was commissioned right after a row about David Cameron’s election strategist Lynton Crosby, whose lobbying firm represents tobacco interests. PMI, which helps make Marlboro cigarettes and is a client of Crosby’s company, has warned that plain packaging would encourage smuggling.

Even so the new study, published in the journal Tobacco Control, claims such arguments should be viewed sceptically.

Professor Anna Gilmore of the Tobacco Management Study Group at the University of Bath said: “We discovered that from early 2008 until early 2011 there have been definitely no media stories citing sector information on illicit sales of tobacco, despite ranges becoming far higher then than they are now. Then out of the blue, just right after the probability of plain packaging was announced, we noticed an boost in such stories, which have continued given that. This, and the truth that leaked documents demonstrate that illicit trade was to be one of the industry’s crucial arguments towards plain packs, suggests this is a deliberate approach.”

Gilmore explained business claims that the use of illicit cigarettes in the United kingdom was sharply increasing have been “wholly inconsistent” with historical trends and recent independent data.

The paper also states: “There is expanding proof that the tobacco businesses are nonetheless involved in the illicit trade. There is proof of considerable overproduction of cigarettes in markets this kind of as Ukraine and Belarus and we know these extra cigarettes finish up in the illegal marketplace.”

Numerous of the tobacco industry’s claims about smuggled tobacco are based on its own studies examining discarded packs at higher-profile venues this kind of as racecourses and football stadiums. But Gilmore questioned the reliability of this kind of studies.

“Tobacco industry data on the illicit trade is completely unreliable,” she said. “Their methodology is never entirely transparent. Their misleading claims about illicit should be witnessed for what they are – a desperate bid to avoid plain packaging from currently being implemented.”

The industry has been robust in fighting its corner. It has commissioned many studies that claim that standardised packs would see an improve in smuggling – anything that could deprive the Exchequer of billions of lbs. Itfiercely rejects claims that it encourages the offering of its personal merchandise on the black marketplace, pointing out that it money a selection of counter-smuggling initiatives.Official customs figures published earlier this month in Australia, the initial country to introduce plain packs, uncovered that the measure has had virtually no effect on tobacco smuggling. “This offical data from Australian customs is the last nail in the coffin for the tobacco industry’s argument that plain packs will boost illicit,” Gilmore stated. “Yet once more the industry’s lies are exposed.”

Deborah Arnott of overall health charity Ash, mentioned the tobacco industry had paid vast sums to consultancies and thinktanks “to make dubious reviews towards plain standardised packaging of cigarettes, which make up in size what they lack in academic rigour.

“The oft-repeated argument that smuggling will increase if branding is eliminated runs counter to all independent proof and is no longer credible.”

Tobacco companies hype smuggling fears to steer clear of plain packaging, finds review